959583-52-9 Usage
General Description
"(2S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid" is a complex organic compound, typically used in various fields of chemical research and development. Its structure consists of a pyrrolidine ring, a type of cyclic amine, combined with different functional groups such as a tert-butoxycarbonyl (a type of carbamate protecting group), a 4-fluorobenzyl group, and a carboxylic acid at the 2nd position of the ring. The compound’s stereospecificity, denoted by (2S,4R), indicates its specific spatial configuration. It is a critical component in the synthesis of peptides and other complex organic molecules. Outside property data like its density, boiling point, or melting point could vary based on its purity and specific isomers.
Check Digit Verification of cas no
The CAS Registry Mumber 959583-52-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,5,8 and 3 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 959583-52:
(8*9)+(7*5)+(6*9)+(5*5)+(4*8)+(3*3)+(2*5)+(1*2)=239
239 % 10 = 9
So 959583-52-9 is a valid CAS Registry Number.
959583-52-9Relevant articles and documents
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists
Ibrahim, Mohamed A.,Johnson, Henry W. B.,Jeong, Joon Won,Lewis, Gary L.,Shi, Xian,Noguchi, Robin T.,Williams, Matthew,Leahy, James W.,Nuss, John M.,Woolfrey, John,Banica, Monica,Bentzien, Frauke,Chou, Yu-Chien,Gibson, Anna,Heald, Nathan,Lamb, Peter,Mattheakis, Larry,Matthews, David,Shipway, Aaron,Wu, Xiang,Zhang, Wentao,Zhou, Sihong,Shankar, Geetha
, p. 1368 - 1381 (2012/04/04)
A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P 1) antagonists are disclosed. Our high-throughput screening campaign revealed hit 1 for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chemical scaffold. In vivo efficacy revealed that at high doses compounds 12 and 15 inhibited tumor growth. Further optimization of our lead series led to the discovery of proline derivatives 37 (XL541) and 38 which had similar efficacy as our first generation analogues at significantly lower doses. Analogue 37 displayed excellent pharmacokinetics and oral exposure in multiple species.